Coming together for patients
On the surface, the task of data gathering and analysis may not spark excitement.
But when it comes with the possibility of helping people suffering from rare and difficult to treat blood cancers, a routine task becomes life-changing.
And when it perfectly aligns with the strengths of a group like AbbVie’s health economics and outcomes research (HEOR) team, it’s even better.
The HEOR team is deep into data research as part of the company’s commitment to HARMONY Alliance, a European-based public-private partnership formed in early 2017 with the goal of improving treatments for people with blood cancer. The alliance, funded through the Innovative Medicines Initiative (IMI), has attracted about 90 total members and associated partners, from pharmaceutical companies, academics and clinicians to patient advocacy groups, payers and regulatory agencies, all pursuing the same mission for patients.